PharmAthene, SIGA Fight Over Bioterror Defense Drug

Law360, New York (January 3, 2011, 8:35 PM EST) -- PharmAthene Inc. began battling SIGA Technologies Inc. at trial Monday, demanding the erstwhile merger partner fulfill a licensing agreement and share a potential multibillion-dollar federal contract for a smallpox treatment that the U.S. is considering as a defense against bioterror attack.

PharmAthene Vice President of Business Development and Strategy Eric Richman took the stand in the Delaware Court of Chancery, alleging that SIGA refused to honor its obligations under a licensing agreement term sheet after merger talks between the two companies fell through in 2006 and...
To view the full article, register now.